Where AOD 9604 may show more pronounced results is in the context of a structured program that includes caloric management, resistance training, and potentially stacked peptide protocols
No human clinical trials of Dihexa itself have been published in peer-reviewed literature as of 2026
Injections are usually administered subcutaneously (under the skin), once a month, in your vets office
Current Research Limitations Most clinical studies on GHK-Cu involve: Topical formulations In vitro research Animal models Systemic (non-injectable) delivery There is insufficient evidence in peer-reviewed literature to support: standardized injection techniques validated injectable dosing regimens long-term safety or efficacy data for injectable use As a result, clinicians should approach injectable discussions with caution and rely on evidence-based peptide education rather than anecdotal protocols
Suggested dosage may be repeated at 1 to 2 week intervals, as indicated by condition and response
McCarthy are back to separate the facts from the fiction